Full Press Release Details
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38a Kinase Inhibitor Neflamapimod on the Neurodegenerative Process.
CRVO
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38a Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
Key Takeaway: EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38a Kinase Inhibitor Neflamapimod on the Neurodegenerative Process